
PRODUCT INFORMATION

Alisporivir

Item No. 46121



CAS Registry No.:	254435-95-5
Formal Name:	Cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl-(2S)-2-aminobutanoyl-N-methyl-D-alanyl-N-ethyl-L-valyl-L-valyl-N-methyl-L-leucyl]
Synonyms:	DEB025, Debio-025, (D-MeAla3-EtVal4)cyclosporine
MF:	$C_{63}H_{113}N_{11}O_{12}$
FW:	1,216.7
Purity:	≥95%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Alisporivir is supplied as a solid. A stock solution may be made by dissolving the alisporivir in the solvent of choice, which should be purged with an inert gas. Alisporivir is sparingly soluble (1-10 mg/ml) in chloroform and slightly soluble (0.1-1 mg/ml) in acetonitrile and DMSO.

Description

Alisporivir is an inhibitor of peptidyl-prolyl *cis-trans* isomerase A (PPIase A; K_i = 0.34 nM), also known as cyclophilin A (CypA).[1] It inhibits viral replication in HIV-1-infected MT-4 cells and isolated human peripheral blood mononuclear cells (PBMCs; IC_{50}s = 0.099 and 0.064 µM, respectively) but does not have immunosuppressive activity in the $CD4^+$ T cell population in isolated human PBMCs. Alisporivir inhibits hepatitis C virus (HCV) replication in a cell-based replicon assay (EC_{50} = 0.08-0.27 µg/ml) and reduces serum viral titers and viral rebound in a humanized mouse model of HCV infection.[2,3]

References

1. Ptak, R.G., Gallay, P.A., Jochmans, D., *et al.* Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. *Antimicrob. Agents Chemother.* **52(4)**, 1302-1317 (2008).
2. Paeshuyse, J., Kaul, A., De Clercq, E., *et al.* The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication *in vitro*. *Hepatology* **43(4)**, 761-770 (2006).
3. Bobardt, M., Ramirez, C.M., Baum, M.M., *et al.* The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance. *PLoS One* **16(5)**, e0251934 (2021).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/28/2026

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM